NovaBridge to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
NovaBridge's Givastomig Could Drive A Major Re-Rating
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
NovaBridge Biosciences (NBP) Discusses Phase 2a Clinical Data and Development Plan for VIS-101 in Wet Age-Related Macular Degeneration Transcript
Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
What's Going On With NovaBridge Stock Tuesday?
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of I-Mab - IMAB
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
I-Mab (IMAB) Discusses Business Transformation Strategy and Plans for Accelerated Growth Transcript
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
I-Mab Sponsored ADR (IMAB) Is Up 24.14% in One Week: What You Should Know
What Makes IMab (IMAB) a New Buy Stock
I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market
Are You Looking for a Top Momentum Pick? Why I-Mab Sponsored ADR (IMAB) is a Great Choice
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
I-Mab to Participate in September Investor Conferences
Everest Medicines Expands Strategic Investment in I-MAB
I-Mab Announces Pricing of $65 Million Underwritten Offering of American Depositary Shares
I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
I-Mab Sponsored ADR (IMAB)'s Technical Outlook is Bright After Key Golden Cross
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
I-Mab to Present at Jefferies Global Healthcare Conference
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
After Plunging -19.7% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
I-Mab Announces Accelerated Givastomig Phase 1b Study Progress
I-Mab to Participate in Leerink Partners Global Healthcare Conference
I-Mab to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program